NZ514777A - N6 heterocyclic 5'-thio substituted adenosine derivatives - Google Patents

N6 heterocyclic 5'-thio substituted adenosine derivatives

Info

Publication number
NZ514777A
NZ514777A NZ514777A NZ51477700A NZ514777A NZ 514777 A NZ514777 A NZ 514777A NZ 514777 A NZ514777 A NZ 514777A NZ 51477700 A NZ51477700 A NZ 51477700A NZ 514777 A NZ514777 A NZ 514777A
Authority
NZ
New Zealand
Prior art keywords
heterocyclic
group
atom
heterocyclyl
modifying
Prior art date
Application number
NZ514777A
Other languages
English (en)
Inventor
Jeff A Zablocki
Vaibhav Varkhedkar
Luiz Belardinelli
Venkata P Palle
Prabha N Ibrahim
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NZ514777A publication Critical patent/NZ514777A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ514777A 1999-12-03 2000-12-01 N6 heterocyclic 5'-thio substituted adenosine derivatives NZ514777A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
PCT/US2000/032721 WO2001040246A1 (en) 1999-12-03 2000-12-01 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
NZ514777A true NZ514777A (en) 2004-01-30

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514777A NZ514777A (en) 1999-12-03 2000-12-01 N6 heterocyclic 5'-thio substituted adenosine derivatives

Country Status (25)

Country Link
US (2) US6605597B1 (cg-RX-API-DMAC7.html)
EP (1) EP1233973B1 (cg-RX-API-DMAC7.html)
JP (1) JP4021195B2 (cg-RX-API-DMAC7.html)
KR (1) KR100484988B1 (cg-RX-API-DMAC7.html)
CN (1) CN1152042C (cg-RX-API-DMAC7.html)
AR (1) AR029199A1 (cg-RX-API-DMAC7.html)
AT (1) ATE254133T1 (cg-RX-API-DMAC7.html)
AU (3) AU4138701A (cg-RX-API-DMAC7.html)
BR (1) BR0016126A (cg-RX-API-DMAC7.html)
CA (1) CA2389264C (cg-RX-API-DMAC7.html)
CZ (1) CZ20013705A3 (cg-RX-API-DMAC7.html)
DE (1) DE60006576T2 (cg-RX-API-DMAC7.html)
DK (1) DK1233973T3 (cg-RX-API-DMAC7.html)
ES (1) ES2208437T3 (cg-RX-API-DMAC7.html)
HK (1) HK1047941A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0500455A2 (cg-RX-API-DMAC7.html)
IL (1) IL145903A (cg-RX-API-DMAC7.html)
MX (1) MXPA01011113A (cg-RX-API-DMAC7.html)
NO (1) NO20015373L (cg-RX-API-DMAC7.html)
NZ (1) NZ514777A (cg-RX-API-DMAC7.html)
PT (1) PT1233973E (cg-RX-API-DMAC7.html)
TR (2) TR200103129T2 (cg-RX-API-DMAC7.html)
TW (1) TWI249536B (cg-RX-API-DMAC7.html)
WO (2) WO2001040243A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204380B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ,インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1802317A2 (en) * 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
MX2009002299A (es) * 2006-09-01 2009-03-20 Cv Therapeutics Inc Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 a-2-알파 수용체 길항제와 속도 조절제의 조합물
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
CN1065529C (zh) * 1994-06-09 2001-05-09 爱斯制药株式会社 4-喹啉酮衍生物及其盐
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives

Also Published As

Publication number Publication date
NO20015373D0 (no) 2001-11-02
PT1233973E (pt) 2004-02-27
JP2003516325A (ja) 2003-05-13
CN1378550A (zh) 2002-11-06
CN1152042C (zh) 2004-06-02
TWI249536B (en) 2006-02-21
ATE254133T1 (de) 2003-11-15
DK1233973T3 (da) 2004-02-16
EP1233973A1 (en) 2002-08-28
DE60006576T2 (de) 2004-09-16
DE60006576D1 (de) 2003-12-18
BR0016126A (pt) 2002-08-06
WO2001040246A1 (en) 2001-06-07
AU4138701A (en) 2001-06-12
TR200103129T2 (tr) 2002-10-21
WO2001040243A3 (en) 2001-12-13
US6605597B1 (en) 2003-08-12
CA2389264C (en) 2007-03-06
WO2001040243A2 (en) 2001-06-07
ES2208437T3 (es) 2004-06-16
HUP0500455A2 (hu) 2005-08-29
AU7938301A (en) 2002-03-21
MXPA01011113A (es) 2002-06-04
US20050054605A1 (en) 2005-03-10
KR100484988B1 (ko) 2005-04-22
KR20030032907A (ko) 2003-04-26
TR200301971T4 (tr) 2004-01-21
IL145903A (en) 2006-04-10
AU761029B2 (en) 2003-05-29
EP1233973B1 (en) 2003-11-12
ZA200204380B (en) 2003-06-25
AR029199A1 (es) 2003-06-18
CA2389264A1 (en) 2001-06-07
AU1811701A (en) 2001-06-12
JP4021195B2 (ja) 2007-12-12
NO20015373L (no) 2001-11-29
CZ20013705A3 (cs) 2002-04-17
HK1047941A1 (zh) 2003-03-14

Similar Documents

Publication Publication Date Title
BR9801020A (pt) Derivados de azaindol-etilamina como agentes de ligação do receptor de acetilcolina nicotìnico.
Leschke et al. Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogs
CA2123403A1 (en) Acyclic ethylenediamine derivatives as substance p receptor antagonists
EP1221443A4 (en) SUBSTITUTED IMIDAZOLINE DERIVATIVES
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
CA2131797A1 (en) Condensed indole derivatives as 5ht4-receptor antagonists
TW200716528A (en) Cyclopropanecarboxamide derivatives
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
TWI265164B (en) 3-substituted-4-pyrimidone derivatives
TR200100378T2 (tr) P-maddesi aşırısının aracılık ettiği hastalıkların tedavisindeki ilaç
MXPA02011418A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico.
KR920002604A (ko) 디카르복스이미드, 그의 제조 방법 및 제초제로서의 그의 용도
ATE526018T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
NZ334548A (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists
BR0016951A (pt) Derivado de fenilpiperazinil, composto, composição farmacêutica, uso do mesmo, método de tratamento
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
AU7950100A (en) 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
MXPA06003748A (es) Compuestos de lactama condensada.
EP1219621A4 (en) AZAINDOLIZINONE DERIVATIVES AND AGENTS TO IMPROVE CERBRAL PERFORMANCE, WHICH CONTAINS THE SAME AS ACTIVE INGREDIENTS
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
KR830009069A (ko) 알카놀아민 유도체의 제조방법
AU3648093A (en) Pyrrolidine derivatives useful as 5-HT3-antagonists
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden

Legal Events

Date Code Title Description
RENP Pct: late entry into national phase requested

Effective date: 20011012

ASS Change of ownership

Owner name: CV THERAPEUTICS, INC., US

Free format text: OLD OWNER(S): CV THERAPEUTICS, INC.; PRABHA N. IBRAHIM

LENP Pct: late entry into national phase granted

Effective date: 20011012

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)